

## Special Issue

# Epidemiology of COVID-19

### Message from the Guest Editors

The Coronavirus disease- 2019 (COVID-19) pandemic, caused by the novel virus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has had devastating consequences worldwide, with over one hundred million cases confirmed and nearly 2.3 million deaths reported as of February 3, 2021. The complex and heterogeneous expansion of the pandemic has highlighted the critical importance of global surveillance efforts and science-based public health decision-making and policies. Recently, the description of virus variants and emergent lineages has raised concerns regarding increased infectivity and virulence, potentially reshaping the epidemiologic landscape of this disease. This special issue will present emerging concepts regarding the epidemiology, prevention and control of SARS-CoV-2 infection, with special focus on ecological & evolutionary factors in virus emergence, host- virus dynamics, and the assessment and implementation of therapeutic and immunization efforts to mitigate disease burden.

---

### Guest Editors

Prof. Dr. Alberto E. Paniz-Mondolfi

Icahn School of Medicine at Mount Sinai, Department of Pathology, Molecular and Cell-Based Medicine, Clinical Microbiology Laboratory, New York, NY 10029, USA

Dr. Emilia Mia Sordillo

Icahn School of Medicine at Mount Sinai, Molecular and Cell-Based Medicine Clinical Microbiology Laboratory, New York, NY 10029, USA

---

### Deadline for manuscript submissions

closed (31 October 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/76567](https://mdpi.com/si/76567)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).